- Home
- LPG vs ELVN Comparison
LPG vs ELVN Comparison
Compare LPG & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPG
- ELVN
- Stock Information
- Founded
- LPG 2013
- ELVN 2016
- Country
- LPG United States
- ELVN United States
- Employees
- LPG N/A
- ELVN N/A
- Industry
- LPG Marine Transportation
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- LPG Consumer Discretionary
- ELVN Health Care
- Exchange
- LPG Nasdaq
- ELVN Nasdaq
- Market Cap
- LPG 1.4B
- ELVN 1.2B
- IPO Year
- LPG 2014
- ELVN 2020
- Fundamental
- Price
- LPG $26.89
- ELVN $21.35
- Analyst Decision
- LPG Strong Buy
- ELVN Strong Buy
- Analyst Count
- LPG 1
- ELVN 5
- Target Price
- LPG $35.00
- ELVN $41.20
- AVG Volume (30 Days)
- LPG 448.3K
- ELVN 414.3K
- Earning Date
- LPG 10-31-2025
- ELVN 11-12-2025
- Dividend Yield
- LPG 11.90%
- ELVN N/A
- EPS Growth
- LPG N/A
- ELVN N/A
- EPS
- LPG 1.15
- ELVN N/A
- Revenue
- LPG $320,692,009.00
- ELVN N/A
- Revenue This Year
- LPG $17.26
- ELVN N/A
- Revenue Next Year
- LPG N/A
- ELVN $20.05
- P/E Ratio
- LPG $23.36
- ELVN N/A
- Revenue Growth
- LPG N/A
- ELVN N/A
- 52 Week Low
- LPG $16.66
- ELVN $13.30
- 52 Week High
- LPG $33.67
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- LPG 33.02
- ELVN 57.25
- Support Level
- LPG $25.50
- ELVN $19.98
- Resistance Level
- LPG $27.24
- ELVN $22.42
- Average True Range (ATR)
- LPG 0.70
- ELVN 0.95
- MACD
- LPG -0.21
- ELVN 0.17
- Stochastic Oscillator
- LPG 30.54
- ELVN 71.20
About LPG Dorian LPG Ltd.
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece. IT operates in one reportable segment, the international transportation of LPG.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.